Literature DB >> 30572373

Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia.

Christopher Jones1, David Hacker, Jun Xia, Alan Meaden, Claire B Irving, Sai Zhao, Jue Chen, Chunhu Shi.   

Abstract

BACKGROUND: Cognitive behavioural therapy (CBT) is a psychosocial treatment that aims to re-mediate distressing emotional experiences or dysfunctional behaviour by changing the way in which a person interprets and evaluates the experience or cognates on its consequence and meaning. This approach helps to link the person's feelings and patterns of thinking which underpin distress. CBT is now recommended by the National Institute for Health and Care Excellence (NICE) as an add-on treatment for people with a diagnosis of schizophrenia. This review is also part of a family of Cochrane CBT reviews for people with schizophrenia.
OBJECTIVES: To assess the effects of cognitive behavioural therapy added to standard care compared with standard care alone for people with schizophrenia. SEARCH
METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (up to March 6, 2017). This register is compiled by systematic searches of major resources (including AMED, BIOSIS CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings, with no language, date, document type, or publication status limitations for inclusion of records into the register. SELECTION CRITERIA: We selected all randomised controlled clinical trials (RCTs) involving people diagnosed with schizophrenia or related disorders, which compared adding CBT to standard care with standard care given alone. Outcomes of interest included relapse, rehospitalisation, mental state, adverse events, social functioning, quality of life, and satisfaction with treatment.We included studies fulfilling the predefined inclusion criteria and reporting useable data. DATA COLLECTION AND ANALYSIS: We complied with the Cochrane recommended standard of conduct for data screening and collection. Where possible, we calculated relative risk (RR) and its 95% confidence interval (CI) for binary data and mean difference (MD) and its 95% confidence interval for continuous data. We assessed risk of bias for included studies and created a 'Summary of findings' table using GRADE. MAIN
RESULTS: This review now includes 60 trials with 5,992 participants, all comparing CBT added to standard care with standard care alone. Results for the main outcomes of interest (all long term) showed no clear difference between CBT and standard care for relapse (RR 0.78, 95% CI 0.61 to 1.00; participants = 1538; studies = 13, low-quality evidence). Two trials reported global state improvement. More participants in the CBT groups showed clinically important improvement in global state (RR 0.57, 95% CI 0.39 to 0.84; participants = 82; studies = 2 , very low-quality evidence). Five trials reported mental state improvement. No differences in mental state improvement were observed (RR 0.81, 95% CI 0.65 to 1.02; participants = 501; studies = 5, very low-quality evidence). In terms of safety, adding CBT to standard care may reduce the risk of having an adverse event (RR 0.44, 95% CI 0.27 to 0.72; participants = 146; studies = 2, very low-quality evidence) but appears to have no effect on long-term social functioning (MD 0.56, 95% CI -2.64 to 3.76; participants = 295; studies = 2, very low-quality evidence, nor on long-term quality of life (MD -3.60, 95% CI -11.32 to 4.12; participants = 71; study = 1, very low-quality evidence). It also has no effect on long-term satisfaction with treatment (measured as 'leaving the study early') (RR 0.93, 95% CI 0.77 to 1.12; participants = 1945; studies = 19, moderate-quality evidence). AUTHORS'
CONCLUSIONS: Relative to standard care alone, adding CBT to standard care appears to have no effect on long-term risk of relapse. A very small proportion of the available evidence indicated CBT plus standard care may improve long term global state and may reduce the risk of adverse events. Whether adding CBT to standard care leads to clinically important improvement in patients' long-term mental state, quality of life, and social function remains unclear. Satisfaction with care (measured as number of people leaving the study early) was no higher for participants receiving CBT compared to participants receiving standard care. It should be noted that although much research has been carried out in this area, the quality of evidence available is poor - mostly low or very low quality and we still cannot make firm conclusions until more high quality data are available.

Entities:  

Mesh:

Year:  2018        PMID: 30572373      PMCID: PMC6517137          DOI: 10.1002/14651858.CD007964.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  178 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

Review 2.  Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology.

Authors:  Andrew C Leon; Craig H Mallinckrodt; Christy Chuang-Stein; Donald G Archibald; Graeme E Archer; Kevin Chartier
Journal:  Biol Psychiatry       Date:  2006-02-28       Impact factor: 13.382

Review 3.  When symptoms persist: choosing among alternative somatic treatments for schizophrenia.

Authors:  G W Christison; D G Kirch; R J Wyatt
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

4.  Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia.

Authors:  Douglas Turkington; David Kingdon; Shanaya Rathod; Katie Hammond; Jeremy Pelton; Raj Mehta
Journal:  Br J Psychiatry       Date:  2006-07       Impact factor: 9.319

Review 5.  Antipsychotic drugs: clinical pharmacology and therapeutic use.

Authors:  J M Davis; R Casper
Journal:  Drugs       Date:  1977-10       Impact factor: 9.546

6.  Efficacy of cognitive nursing intervention for voice hearing.

Authors:  Margaret England
Journal:  Perspect Psychiatr Care       Date:  2007-04       Impact factor: 2.186

7.  Tayside-Fife clinical trial of cognitive-behavioural therapy for medication-resistant psychotic symptoms. Results to 3-month follow-up.

Authors:  Robert C Durham; Moyra Guthrie; R Victor Morton; David A Reid; Linda R Treliving; David Fowler; Ranald R Macdonald
Journal:  Br J Psychiatry       Date:  2003-04       Impact factor: 9.319

8.  Staff-patient relationships and outcomes in schizophrenia: the role of staff attributions.

Authors:  Katherine Berry; Lynsey Gregg; Debora Vasconcelos e Sa; Gillian Haddock; Christine Barrowclough
Journal:  Behav Res Ther       Date:  2012-01-25

9.  London-east Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. III: Follow-up and economic evaluation at 18 months.

Authors:  E Kuipers; D Fowler; P Garety; D Chisholm; D Freeman; G Dunn; P Bebbington; C Hadley
Journal:  Br J Psychiatry       Date:  1998-07       Impact factor: 9.319

10.  Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up.

Authors:  Eric Granholm; John R McQuaid; Fauzia Simjee McClure; Peter C Link; Dimitri Perivoliotis; Jennifer D Gottlieb; Thomas L Patterson; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2007-05       Impact factor: 4.384

View more
  10 in total

1.  The controversy about cognitive behavioural therapy for schizophrenia.

Authors:  Peter McKenna; Stefan Leucht; Sammy Jauhar; Keith Laws; Irene Bighelli
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

2.  Sixth Kraepelin Symposium-Understanding and Treating Cognitive Impairment and Depression in Schizophrenia and Affective Disorders.

Authors:  Schaub Annette; Falkai Peter
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

Review 3.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

Review 4.  Cognitive behavioural therapy (group) for schizophrenia.

Authors:  Giuseppe Guaiana; Massimiliano Abbatecola; Ghazaleh Aali; Federica Tarantino; Ikenna D Ebuenyi; Valeria Lucarini; Wei Li; Caidi Zhang; Antonio Pinto
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

Review 5.  Humour-based interventions for people with schizophrenia.

Authors:  Yasushi Tsujimoto; Yuri Nakamura; Masahiro Banno; Kunihiro Kohmura; Hiraku Tsujimoto; Yuki Kataoka
Journal:  Cochrane Database Syst Rev       Date:  2021-10-13

Review 6.  Implementation Science is Imperative to the Optimization of Obstetric Care.

Authors:  Rebecca F Hamm; Brian K Iriye; Sindhu K Srinivas
Journal:  Am J Perinatol       Date:  2020-12-15       Impact factor: 3.079

7.  Non-pharmacological interventions for schizophrenia-analysis of treatment guidelines and implementation in 12 Southeast European countries.

Authors:  Lidija Injac Stevović; Selman Repišti; Tamara Radojičić; Norman Sartorius; Sonila Tomori; Alma Džubur Kulenović; Ana Popova; Martina Rojnić Kuzman; Ilias I Vlachos; Shukrije Statovci; Alexei Bandati; Antoni Novotni; Stojan Bajraktarov; Anca-Livia Panfil; Nadja Maric; Mirjana Delić; Nikolina Jovanović
Journal:  Schizophrenia (Heidelb)       Date:  2022-03-01

8.  [Stoma-associated complications-Prevention strategy and treatment concepts].

Authors:  Georgi Kalev; Christoph Marquardt; Thomas Schiedeck
Journal:  Chirurg       Date:  2021-06-17       Impact factor: 0.955

9.  Prophylactic retromuscular mesh placement for parastomal hernia prevention: a retrospective cohort study of permanent colostomies and ileostomies.

Authors:  Jonathan Frigault; Simon Lemieux; Dominic Breton; Philippe Bouchard; Alexandre Bouchard; Roger C Grégoire; François Letarte; Gilles Bouchard; Vincent Boun; Katia Massé; Sébastien Drolet
Journal:  Hernia       Date:  2021-06-16       Impact factor: 4.739

10.  Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence.

Authors:  Irene Bighelli; Alessandro Rodolico; Gabi Pitschel-Walz; Wulf-Peter Hansen; Corrado Barbui; Toshi A Furukawa; Georgia Salanti; Stefan Leucht
Journal:  BMJ Open       Date:  2020-01-19       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.